Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma

被引:2
|
作者
Nakayama, Sayuka [1 ]
Masuda, Hiroko [1 ]
Miura, Sakiko [2 ]
Kuwayama, Takashi [1 ]
Hashimoto, Rikako [1 ]
Taruno, Kanae [1 ]
Sawada, Terumasa [3 ]
Akashi-Tanaka, Sadako [1 ]
Nakamura, Seigo [1 ]
机构
[1] Showa Univ Hosp, Dept Breast Surg Oncol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan
[2] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan
[3] NTT Med Ctr Tokyo, Dept Breast Surg Oncol, Tokyo, Japan
关键词
Ductal carcinoma in situ; LORETTA trial; Low-grade DCIS; Overtreatment; Active surveillance; CORE-NEEDLE BIOPSY; LYMPH-NODE BIOPSY; BREAST-CANCER; KI-67; EXPRESSION; PREDICTORS; UNDERESTIMATION; MAMMOGRAPHY; METASTASIS; RECURRENCE; MANAGEMENT;
D O I
10.1007/s12282-022-01338-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Prospective cohort studies are being conducted worldwide to identify a low-grade group of ductal carcinoma in situ (DCIS) that does not require surgery. However, to do this, it is necessary to predict which cases, diagnosed with preoperative DCIS, will be upgraded to invasive ductal carcinoma (IDC) after surgery. Methods In this study, we evaluated the frequency of IDC upgrades in patients who were preoperatively diagnosed with DCIS at Showa University using the criteria of ongoing clinical trials. We divided our cases into those that could be enrolled in the ongoing trial and those that could not. Moreover, we evaluated whether CNB, which is allowed only in Japanese clinical trials, is related to the IDC mixture. Results There were 211 (52.1%) cases that matched the criteria of the U.K. and Netherlands trials, of which 62 (29.4%) were upgraded to IDC. A total of 113 (27.9%) cases met the criteria for clinical trials in Japan and the U.S., 25 (22.1%) of which were upgraded to IDC and 47 (34.6%) which matched when considering biopsy methods. The number of cases upgraded to IDC decreased to four (8.5%). Conclusions This study demonstrated that there were a certain number of mixed IDC. We will pay attention to the results of ongoing clinical trials regarding how the presence of this mixed IDC affects the prognosis in non-surgery cases. Careful follow-up is recommended for non-surgical treatment.
引用
收藏
页码:610 / 617
页数:8
相关论文
共 50 条
  • [21] Do not contemplate invasive surgery for ductal carcinoma in situ
    Zelis, JJ
    Sickle-Santanello, BJ
    Liang, WC
    Nims, TA
    AMERICAN JOURNAL OF SURGERY, 2002, 184 (04): : 348 - 349
  • [22] Molecular phenotypes of ductal carcinoma-in-situ and invasive ductal carcinoma: A comparative study
    Gupta, Shilpa
    Deka, Lopamudra
    Gupta, Ruchika
    Pant, Leela
    Singh, Sompal
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2012, 55 (01) : 43 - 46
  • [23] Management of Ductal Carcinoma In Situ: Opportunities for De-Escalation of Surgery, Radiation, and Treatment
    Siegel, Emily L.
    Carr, Azadeh A.
    CURRENT BREAST CANCER REPORTS, 2024, 16 (03) : 336 - 341
  • [24] Expression of HER-2/neu and Paxillin in Ductal Carcinoma in situ, Invasive Ductal Carcinoma with Ductal Carcinoma in situ and Mucinous Carcinoma
    Han, Sun-Wook
    Choi, Yoon-Young
    Woo, Hee-Doo
    Sohn, Doo-Min
    Bae, Sang-Ho
    Gang, Gil-Ho
    Kim, Sung-Yong
    Back, Moo-Jun
    Lim, Cheol-Wan
    Lee, Moon-Soo
    Kim, Chang-Ho
    Lee, Min-Hyuk
    Rho, Jin-Hyuk
    Cho, Hyun-Deuk
    Oh, Mee Hye
    Kim, Eui-Han
    Cho, Moo-Sik
    JOURNAL OF BREAST CANCER, 2008, 11 (03) : 109 - 115
  • [25] Ductal carcinoma in situ of breast: update 2019
    Badve, Sunil S.
    Gokmen-Polar, Yesim
    PATHOLOGY, 2019, 51 (06) : 563 - 569
  • [26] Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study
    Tanaka, Kiyo
    Masuda, Norikazu
    Hayashi, Naoki
    Sagara, Yasuaki
    Hara, Fumikata
    Kadoya, Takayuki
    Matsui, Akira
    Miyazaki, Chieko
    Shien, Tadahiko
    Tokunaga, Eriko
    Hayashi, Takako
    Niikura, Naoki
    Maeda, Shigeto
    Komoike, Yoshihumi
    Bando, Hiroko
    Kanbayashi, Chizuko
    Iwata, Hiroji
    BREAST CANCER, 2021, 28 (04) : 896 - 903
  • [27] Sentinel lymph nodes and ductal carcinoma in situ
    de Lara, C. Tunon
    Fournier, M.
    Macgrogan, G.
    ONCOLOGIE, 2013, 15 (06) : 331 - 335
  • [28] Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
    Oseni, Tawakalitu O.
    Smith, Barbara L.
    Lehman, Constance D.
    Vijapura, Charmi A.
    Pinnamaneni, Niveditha
    Bahl, Manisha
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (11) : 4459 - 4465
  • [29] An MRI-Based Radiomics Nomogram to Distinguish Ductal Carcinoma In Situ with Microinvasion From Ductal Carcinoma In Situ of Breast Cancer
    Wu, Zengjie
    Lin, Qing
    Wang, Haibo
    Wang, Guanqun
    Fu, Guangming
    Bian, Tiantian
    ACADEMIC RADIOLOGY, 2023, 30 : S71 - S81
  • [30] Current approach and future perspective for ductal carcinoma in situ of the breast
    Kanbayashi, Chizuko
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (08) : 671 - 677